Trump Pushes for Faster Cannabis Rescheduling Progress
President expresses urgency on cannabis policy reform four months after initial directive, signaling potential acceleration of federal rescheduling timeline.
President Trump publicly urged federal agencies to expedite cannabis rescheduling efforts, marking his most direct intervention since issuing the initial directive four months ago. The president's plea for agencies to "please" accelerate the process suggests mounting pressure to deliver on campaign promises that helped secure support from cannabis industry stakeholders and reform advocates.
The timeline delay highlights the complex bureaucratic machinery involved in rescheduling cannabis from Schedule I to Schedule III under the Controlled Substances Act. The Drug Enforcement Administration and Department of Health and Human Services must navigate extensive regulatory reviews, public comment periods, and interagency coordination that typically spans 12-18 months for controlled substance modifications.
Cannabis operators face continued uncertainty as the rescheduling process extends beyond initial expectations. Multi-state operators like Curaleaf (OTCQX: CURLF), Green Thumb Industries (OTCQX: GTBIF), and Trulieve (OTCQX: TCNNF) continue operating under Section 280E tax restrictions that prevent standard business deductions, significantly impacting profit margins across the sector.
The president's public pressure campaign reflects growing impatience from industry participants who expected faster regulatory movement following the election. Cannabis stocks have experienced volatility as investors weigh reform timelines against operational challenges, with many operators burning cash while awaiting federal policy clarity that could unlock banking access and interstate commerce.
Trump's direct appeal signals potential executive branch intervention to streamline agency processes, though constitutional separation of powers limits presidential authority over independent regulatory proceedings. The administration's ability to influence timing without compromising legal integrity of the rescheduling review will determine whether cannabis companies see relief in 2025 or face extended regulatory limbo that continues pressuring sector valuations and growth prospects.